Volume 39 Issue 12, December 2021

In China, the first children with germline-edited genomes are growing up. How might their edited genomes affect their lives?

Whether pan-vaccines or antibodies, SARS-CoV-2 is adding impetus to the race for broad-spectrum countermeasures against the world’s next infectious scourges.

As pharmaceutical companies seek patent protection for combinations of cancer therapeutics, it is worthwhile to assess what constitutes an ‘unexpected result’ for the purpose of an appropriate patent and whether randomized, controlled trials of drug combinations have the ability to generate them.

Recent patents relating to wearable technology and devices for patient monitoring and treatment.

Single-cell transcriptomes are accurately sequenced with error-tolerant barcodes.

A whole monkey brain is imaged at high resolution in 100 hours.

Genes in the rodent brain are knocked down by DNA/RNA heteroduplexes injected intravenously.

The sensitivity of circulating tumor DNA detection is improved by identifying sequences with two or more mutations.

A high-fidelity mirror-image polymerase that accurately synthesizes mirror-image DNA protects stored information from biodegradation.

SARS-CoV-2 detection with LAMP-Seq combines isothermal amplification and barcoding with high-throughput sequencing.

The software platform MaxDIA streamlines analysis of data-independent acquisition proteomics.

The number of usable reads in single-cell DNA and chromatin assays is increased by adapter switching.

Rice and potato plants are more productive after epitranscriptome engineering.

Cancer mutations in non-unique sequences are identified by machine learning on short-read data.

Eighteen years after its inception, the international Genetically Engineered Machine competition has catalyzed the infusion of synthetic biology with interdisciplinary fundamental and translational research, as well as with inspired young scientists.

Recent moves of note in and around the biotech and pharma industries.